Banco BTG Pactual S.A. Has $1.23 Million Holdings in Natera, Inc. $NTRA

Key Points

• Banco BTG Pactual S.A. reduced its stake in Natera, Inc. by 25.5%, selling 2,975 shares and holding a total of 8,669 shares valued at approximately $1.23 million.
• Natera, Inc. reported a loss of $0.74 EPS in its last earnings report, missing analyst estimates, but achieved $546.6 million in revenue, exceeding expectations by over $69 million.
• Despite mixed recent earnings results, Natera's stock has remained popular among analysts, with multiple firms maintaining an "overweight" rating and a consensus price target of approximately $193.19.

Banco BTG Pactual S.A. lessened its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 25.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,669 shares of the medical research company's stock after selling 2,975 shares during the period. Banco BTG Pactual S.A.'s holdings in Natera were worth $1,226,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Natera by 0.6% in the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company's stock worth $1,752,611,000 after buying an additional 77,357 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Natera by 9.9% in the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after purchasing an additional 660,538 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Natera by 134.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. Invesco Ltd. boosted its holdings in Natera by 13.7% in the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company's stock worth $287,908,000 after purchasing an additional 245,719 shares during the period. Finally, Lord Abbett & CO. LLC boosted its holdings in Natera by 5.6% in the first quarter. Lord Abbett & CO. LLC now owns 1,521,300 shares of the medical research company's stock worth $215,127,000 after purchasing an additional 80,865 shares during the period. Institutional investors own 99.90% of the company's stock.

Natera Trading Up 2.3%

NTRA stock traded up $3.65 during trading on Friday, hitting $165.60. The company had a trading volume of 839,847 shares, compared to its average volume of 1,655,524. The business has a 50 day moving average of $154.85 and a 200 day moving average of $154.16. Natera, Inc. has a fifty-two week low of $110.57 and a fifty-two week high of $183.00. The firm has a market capitalization of $22.73 billion, a price-to-earnings ratio of -86.70 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. During the same quarter last year, the firm posted ($0.30) earnings per share. Natera's revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

NTRA has been the subject of several analyst reports. UBS Group boosted their price target on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Royal Bank Of Canada boosted their price target on shares of Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price target for the company in a report on Monday, July 28th. Piper Sandler reissued an "overweight" rating and set a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Finally, Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. One research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $193.19.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 678 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $105,401.88. Following the sale, the insider directly owned 152,747 shares in the company, valued at approximately $23,746,048.62. The trade was a 0.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 2,496 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $133.17, for a total transaction of $332,392.32. Following the completion of the sale, the director owned 5,763 shares in the company, valued at approximately $767,458.71. This trade represents a 30.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 61,792 shares of company stock valued at $9,227,972 in the last quarter. 5.63% of the stock is owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.